Immunotherapy in Autoimmune Diseases: Current Advances and Future Directions

Immunotherapy represents a novel approach for managing autoimmune diseases by targeting specific immune cells, cytokines, and checkpoints rather than broadly suppressing the immune system. Corticosteroids and disease-modifying antirheumatic drugs (DMARDs) remain commonly used treatments despite challenges such as lack of specificity and significant adverse effects. Immunotherapies, including monoclonal antibodies (mAbs), CAR-T cells, and immune checkpoint inhibitors (ICIs), address the underlying causes of immune system dysfunction, offering enhanced effectiveness for conditions such as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and psoriasis. Emerging therapies include next-generation CAR-T and CAR-NK cells, gene editing technologies such as CRISPR, and personalized medicine approaches. These innovations allow for precise targeting of autoreactive cells and customization of treatments to individual immune profiles. Although the advances are promising, safety issues, high costs, and the variability in patient response are still the major hurdles. Key challenges include immune-related adverse events and infections, while economic barriers significantly limit accessibility. Additionally, variability in therapeutic outcomes highlights the need for biomarkers to predict responses and guide patient selection. AI-based tools could aid patient stratification and drug discovery, enhancing safety and efficacy in the future. Overall, sustained exploration in immunotherapy optimization and the introduction of new concepts are of utmost importance for the purpose of autoimmune disease management. Furthermore, these advancements hold the potential to extend remission duration and improve patient quality of life.